Ibrutinib and Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death
Background: The natural history of chronic lymphocytic leukemia (CLL) was dramatically
improved by the introduction of ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. In this …
improved by the introduction of ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. In this …
Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real‐world analysis from the Chronic Lymphocytic …
M Špaček, L Smolej, M Šimkovič… - British Journal of …, 2023 - Wiley Online Library
Summary Idelalisib (idela), a phosphatidylinositol 3‐kinase inhibitor, and ibrutinib, a Bruton
tyrosine kinase inhibitor, were the first oral targeted agents approved for relapsed/refractory …
tyrosine kinase inhibitor, were the first oral targeted agents approved for relapsed/refractory …
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study
FR Mauro, PR Scalzulli, L Scarfò, C Minoia, R Murru… - Cancers, 2024 - mdpi.com
Simple Summary In clinical trials, ibrutinib was found to be effective and well-tolerated in
patients with chronic lymphocytic leukemia (CLL). To confirm these findings, data on …
patients with chronic lymphocytic leukemia (CLL). To confirm these findings, data on …
Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib—A retrospective …
ML Andersson, H Johansson… - European Journal of …, 2023 - Wiley Online Library
Objective Ibrutinib treatment is associated with cardiovascular side effects, in particular atrial
fibrillation (AF) and hypertension, as well as increased risk of bleeding. Here, we aimed at …
fibrillation (AF) and hypertension, as well as increased risk of bleeding. Here, we aimed at …
Real-world characterization of ibrutinib therapy for chronic lymphocytic leukemia and small lymphocytic lymphoma in British Columbia
RS Khelifi - 2022 - open.library.ubc.ca
Background: Ibrutinib therapy has quickly become standard of care in Canada for CLL/SLL
patients, due to its proven survival benefits. Real-world studies, however, have unveiled that …
patients, due to its proven survival benefits. Real-world studies, however, have unveiled that …